Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients
BackgroundDocetaxel is commonly used in breast cancer chemotherapy. The previous drug dose is generally calculated based on body surface area (BSA). However, the metabolism varies greatly among different patients. Docetaxel therapeutic drug monitoring (TDM) helps monitor adverse drug reactions and e...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1563506/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849324186016677888 |
|---|---|
| author | Yongzhe Tang Yongzhe Tang Yamin Liu Yamin Liu Shengying Qin Cong Huai Jin Zhang Jin Zhang Weijie Ding Weijie Ding Junwei Fan Jie Wang Jie Wang Xiaoqing Zhang Xiaoqing Zhang |
| author_facet | Yongzhe Tang Yongzhe Tang Yamin Liu Yamin Liu Shengying Qin Cong Huai Jin Zhang Jin Zhang Weijie Ding Weijie Ding Junwei Fan Jie Wang Jie Wang Xiaoqing Zhang Xiaoqing Zhang |
| author_sort | Yongzhe Tang |
| collection | DOAJ |
| description | BackgroundDocetaxel is commonly used in breast cancer chemotherapy. The previous drug dose is generally calculated based on body surface area (BSA). However, the metabolism varies greatly among different patients. Docetaxel therapeutic drug monitoring (TDM) helps monitor adverse drug reactions and explore the appropriate range of area under the curve (AUC) to ensure chemotherapy effectiveness and reduce adverse reaction occurrence.MethodsWe conducted a real-world retrospective study and included 180 breast cancer patients, who received a chemotherapy regimen containing docetaxel. The patients’ demographic and tumor data were reviewed. Adverse reaction data during chemotherapy treatment were collected through patient questionnaires and laboratory test results. Univariate logistic regression analysis was performed on 33 patient indexes, including basic information, blood toxicity, liver and kidney function, gastrointestinal reactions, and cardiotoxicity.ResultsThe adverse reactions of chemotherapy were matched with different docetaxel AUC results through univariate analysis. The patients between the groups were no statistically significant differences in terms of demographic and tumor data, including age, height, weight, BSA, and body mass index (p > 0.05). Univariate analysis revealed significant differences in albumin (ALB) levels (p = 0.037), creatinine (CREA) levels (p = 0.002), nausea occurrence (p = 0.008), vomiting occurrence (p = 0.013), rashes occurrence (p = 0.002), and chemotherapy-induced alopecia incidence (CIA) (p = 0.002). Based on the results of the univariate analysis, binary logistic regression analysis was further conducted to identify predictors contributing to the occurrence of chemotherapy adverse reactions. The results demonstrated that an AUC value greater than 2.5 mg h/L was significantly associated with increased risk of certain adverse reactions such as rashes, CIA, CREA, and ALB.ConclusionThe docetaxel TDM provides a reliable basis for monitoring chemotherapy adverse reactions, with high AUC significantly associated with certain adverse reactions. Future studies are expected to include more patients and conduct multi-center trials to obtain a suitable AUC range for Chinese patients, which will guide the determination of clinical chemotherapy doses and reduce the occurrence of adverse reactions. |
| format | Article |
| id | doaj-art-c917fd8080d34df69004eb8b5314bef6 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-c917fd8080d34df69004eb8b5314bef62025-08-20T03:48:47ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-05-011610.3389/fphar.2025.15635061563506Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patientsYongzhe Tang0Yongzhe Tang1Yamin Liu2Yamin Liu3Shengying Qin4Cong Huai5Jin Zhang6Jin Zhang7Weijie Ding8Weijie Ding9Junwei Fan10Jie Wang11Jie Wang12Xiaoqing Zhang13Xiaoqing Zhang14Department of Breast Surgery, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaShanghai Key Laboratory of Embryo Original Diseases, Shanghai, ChinaShanghai Key Laboratory of Embryo Original Diseases, Shanghai, ChinaDepartment of Pharmacy, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaKey Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Bio-X Institutes, Shanghai Jiao Tong University, Shanghai, ChinaKey Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Bio-X Institutes, Shanghai Jiao Tong University, Shanghai, ChinaShanghai Key Laboratory of Embryo Original Diseases, Shanghai, ChinaDepartment of Pharmacy, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaShanghai Key Laboratory of Embryo Original Diseases, Shanghai, ChinaDepartment of Pharmacy, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of General Surgery, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Breast Surgery, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaShanghai Key Laboratory of Embryo Original Diseases, Shanghai, ChinaShanghai Key Laboratory of Embryo Original Diseases, Shanghai, ChinaDepartment of Pharmacy, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaBackgroundDocetaxel is commonly used in breast cancer chemotherapy. The previous drug dose is generally calculated based on body surface area (BSA). However, the metabolism varies greatly among different patients. Docetaxel therapeutic drug monitoring (TDM) helps monitor adverse drug reactions and explore the appropriate range of area under the curve (AUC) to ensure chemotherapy effectiveness and reduce adverse reaction occurrence.MethodsWe conducted a real-world retrospective study and included 180 breast cancer patients, who received a chemotherapy regimen containing docetaxel. The patients’ demographic and tumor data were reviewed. Adverse reaction data during chemotherapy treatment were collected through patient questionnaires and laboratory test results. Univariate logistic regression analysis was performed on 33 patient indexes, including basic information, blood toxicity, liver and kidney function, gastrointestinal reactions, and cardiotoxicity.ResultsThe adverse reactions of chemotherapy were matched with different docetaxel AUC results through univariate analysis. The patients between the groups were no statistically significant differences in terms of demographic and tumor data, including age, height, weight, BSA, and body mass index (p > 0.05). Univariate analysis revealed significant differences in albumin (ALB) levels (p = 0.037), creatinine (CREA) levels (p = 0.002), nausea occurrence (p = 0.008), vomiting occurrence (p = 0.013), rashes occurrence (p = 0.002), and chemotherapy-induced alopecia incidence (CIA) (p = 0.002). Based on the results of the univariate analysis, binary logistic regression analysis was further conducted to identify predictors contributing to the occurrence of chemotherapy adverse reactions. The results demonstrated that an AUC value greater than 2.5 mg h/L was significantly associated with increased risk of certain adverse reactions such as rashes, CIA, CREA, and ALB.ConclusionThe docetaxel TDM provides a reliable basis for monitoring chemotherapy adverse reactions, with high AUC significantly associated with certain adverse reactions. Future studies are expected to include more patients and conduct multi-center trials to obtain a suitable AUC range for Chinese patients, which will guide the determination of clinical chemotherapy doses and reduce the occurrence of adverse reactions.https://www.frontiersin.org/articles/10.3389/fphar.2025.1563506/fullDocetaxelTDM (therapeutic drug monitoring)AUC (area under the curve)adverse reactionsbreast cancer |
| spellingShingle | Yongzhe Tang Yongzhe Tang Yamin Liu Yamin Liu Shengying Qin Cong Huai Jin Zhang Jin Zhang Weijie Ding Weijie Ding Junwei Fan Jie Wang Jie Wang Xiaoqing Zhang Xiaoqing Zhang Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients Frontiers in Pharmacology Docetaxel TDM (therapeutic drug monitoring) AUC (area under the curve) adverse reactions breast cancer |
| title | Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients |
| title_full | Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients |
| title_fullStr | Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients |
| title_full_unstemmed | Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients |
| title_short | Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients |
| title_sort | correlation analysis of pharmacokinetic parameters of docetaxel auc and adverse reactions in breast cancer patients |
| topic | Docetaxel TDM (therapeutic drug monitoring) AUC (area under the curve) adverse reactions breast cancer |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1563506/full |
| work_keys_str_mv | AT yongzhetang correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT yongzhetang correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT yaminliu correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT yaminliu correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT shengyingqin correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT conghuai correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT jinzhang correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT jinzhang correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT weijieding correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT weijieding correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT junweifan correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT jiewang correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT jiewang correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT xiaoqingzhang correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients AT xiaoqingzhang correlationanalysisofpharmacokineticparametersofdocetaxelaucandadversereactionsinbreastcancerpatients |